Óscar (@oscarmoralejoMD) profile picture

Óscar

@oscarmoralejoMD

Ap. Digestivo - Unidad Enfermedad Inflamatoria Intestinal - Hospital Universitario de Toledo

Joined May 2024
  • Tweets350
  • Following103
  • Followers86
100Media
Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)Photo by Óscar (@oscarmoralejoMD)
Óscar retweeted
GETECCU (@geteccu) profile picture
GETECCU
@geteccuOct 29
Desde GETECCU, queremos trasladar nuestras más sinceras condolencias a las personas afectadas por el accidente de Urda (Toledo). Acompañamos en el dolor a las familias y allegados y deseamos una pronta recuperación a los heridos. Todo nuestro apoyo en estos momentos difíciles.
Image from GETECCU (@geteccu)
13
17
569
🧪 El Servicio de @DigestivoToledo del Hospital de Toledo organiza un curso sobre prótesis digestivas mínimamente invasivas, con especialistas de toda España. ✅ Dirigido por el Dr. Alejandro Repiso, ha incluido casos clínicos en directo y talleres prácticos. #SomosHUT
Image from Hospital Universitario de Toledo (@HUnivTO)
1
4
290
Estupenda Sesión General por las dras. Jarrín y Cárdenas sobre #trasplantehepático @HUnivTO @BiblioCHT @DigestivoToledo #liver #livertransplantation
Image from Óscar (@oscarmoralejoMD)
Image from Óscar (@oscarmoralejoMD)
Image from Óscar (@oscarmoralejoMD)
1
9
269
Óscar retweeted
GETECCU (@geteccu) profile picture
GETECCU
@geteccuOct 20
Replying to @geteccu @MJCasanovaG @alehndezc @santigarcial
🗣️@oscarmoralejoMD presenta el estudio DIALHATI del Grupo Joven de GETECCU. Analiza la hepatitis autoinmune inducida por anti-TNF en pacientes con EII. En la mayoría de los casos fue leve y se resolvió al retirar el fármaco y/o con corticoides #UEGWeek
Image from GETECCU (@geteccu)
1
1
5
126
Óscar retweeted
GETECCU (@geteccu) profile picture
GETECCU
@geteccuOct 20
¡Enhorabuena a @CRubindecelix , que ha recibido el premio a la mejor presentación en la sesión de pósteres moderados “Therapeutics in IBD: Real-world experience”! 👏👏 Ha presentado U-PARIS, un estudio de ENEIDA que compara upadacitinib y risankizumab en Crohn tras fallo a anti-TNF #UEGWeek
Image from GETECCU (@geteccu)
Image from GETECCU (@geteccu)
2
7
23
742
Sesión General 21/10/2026: Trasplante hepático ¿A quién, cuándo y cómo? 08:15 h-Salón de Actos #HUT •Ponentes: Vanessa Camila Jarrón, Jenny Victoria Cárdenas •Secretaria: Gema de la Cruz Pérez •Servicio: APARATO DIGESTIVO #sesionesCHUT
Sesión General 21/10/2026: Trasplante hepático ¿A quién, cuándo y cómo? A las 08:15 h en el Salón de Actos #HUT #sesionesCHUT

ALT Sesión General 21/10/2026: Trasplante hepático ¿A quién, cuándo y cómo? A las 08:15 h en el Salón de Actos #HUT #sesionesCHUT

1
1
3
202
Breaking results from the VERDICT trial presented by Vipul Jairath! Stringent treat-to-target strategies (Endo & histo remission) significantly reduced UC-related complications vs symptom-based targets (HR 0.33 & 0.30). A landmark study for UC management! #IBD #UEGWeek @my_ueg
Image from Taku Kobayashi (@TakuKobayashiM1)
1
7
2
36
22,213
Óscar retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMOct 17
Monoclonal antibodies targeting the interleukin-23 pathway, given intravenously or subcutaneously, are effective in inflammatory bowel disease. Research findings from the ANTHEM-UC trial are summarized in a new Quick Take video. nej.md/4s4CROE
A visual representation of the ANTHEM-UC trial, which evaluated the safety and efficacy of icotrokinra, a first-in-class, targeted oral peptide that blocks the interleukin-23 receptor, in participants with ulcerative colitis.

ALT A visual representation of the ANTHEM-UC trial, which evaluated the safety and efficacy of icotrokinra, a first-in-class, targeted oral peptide that blocks the interleukin-23 receptor, in participants with ulcerative colitis.

2
20
1
102
22,394
Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD - The Lancet Gastroenterology & Hepatology PUBLISHED TODAY! 😃🤓 thelancet.com/journals/langa…
Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the Intern...

Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the Intern...

Since Selecting Therapeutic Targets in Inflammatory Bowel Disease-II (STRIDE-II), new evidence has become available across inflammatory and patient-centred outcomes. We aimed to update the STRIDE...

thelancet.com
1
1
133
Satisfied with our production for #UEGWeek where @HUnivTO either leads or collaborates in all these 18 communications @abanades_maria @Gema_gga93 @DraMartaRomero congratulations to my colleges! @my_ueg @BiblioCHT
1
5
263
CONCOMITANT INFLAMMATORY BOWEL DISEASE AND EOSINOPHILIC ESOPHAGITIS (CECIBDEE): A MULTICENTRE GETECCU STUDY - Our college @Gema_gga93 collaborates in this study @geteccu @HUnivTO @BiblioCHT #UEGWeek @my_ueg
Image from Óscar (@oscarmoralejoMD)
1
7
225
PREDICTORS OF STEROID FAILURE AND OUTCOMES OF RESCUE THERAPY IN SEVERE IMMUNE CHECKPOINT INHIBITORS-INDUCED COLITIS: A MULTICENTER STUDY FROM GETECCU - Happy to collaborate with @DiegoCasas8 #REGICstudy @geteccu @my_ueg @HUnivTO @BiblioCHT #uegweek2026
Image from Óscar (@oscarmoralejoMD)
3
6
195
IMPACT OF CMV SUPERINFECTION ON THE CLINICAL COURSE OF PATIENTS WITH MODERATE-TO-SEVERE IMMUNE-MEDIATED COLITIS: RESULTS FROM THE REGIC STUDY PROMOTED BY GETECCU - Happy to collaborate with @DiegoCasas8 #REGICstudy @geteccu @my_ueg @HUnivTO @BiblioCHT #uegweek2026
Image from Óscar (@oscarmoralejoMD)
2
5
184
EFFECTIVENESS OF ANTI-TNF THERAPY AFTER A DIFFERENT MECHANISM OF ACTION: REAL-WORLD EVIDENCE FROM THE ENEIDA REGISTRY - Our college @abanades_maria collaborates in this study @DiegoCasas8 @geteccu @my_ueg @HUnivTO @BiblioCHT #UEGWeek #uegweek2026
Image from Óscar (@oscarmoralejoMD)
4
6
248
COMPARATIVE STUDY ON THE EFFECTIVENESS, DURABILITY, AND SAFETY OF UPADACITINIB VERSUS RISANKIZUMAB AFTER ANTI-TNF FAILURE IN CROHN'S DISEASE: THE U-PARIS STUDY OF ENEIDA - Happy to collaborate with @CRubindecelix @geteccu @my_ueg @HUnivTO @BiblioCHT #UEGWeek
Image from Óscar (@oscarmoralejoMD)
1
5
204
IMPORTANCE OF PAIN AS A CLINICAL MANIFESTATION IN THE COURSE AND SEVERITY OF SEVERE IMMUNE-MEDIATED COLITIS: DATA FROM THE GETECCU REGIC STUDY - Happy to collaborate with @DiegoCasas8 #REGICstudy @geteccu @HUnivTO @my_ueg
Image from Óscar (@oscarmoralejoMD)
1
4
114
PREVALENCE OF DYSLIPIDEMIA AND ITS IMPACT ON DIAGNOSTIC CRITERIA FOR WILSON’S DISEASE: ANALYSIS OF THE AEEH REGISTRY - Dra Marta Romero @DraMartaRomero collaborates in this registry #wilsonsdisease @AEEHLiver @HUnivTO @BiblioCHT @my_ueg #UEGWeek #uegweek2026
Image from Óscar (@oscarmoralejoMD)
3
5
225
DRUG-INDUCED AUTOIMMUNE-LIKE HEPATITIS INDUCED BY ANTI-TNF IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE CASE-CONTROL STUDY. THE DIALHATI STUDY FROM GETECCU YOUNG GROUP - Today! Hall 7 Poster Stage 7 16:00 C U there!! 😃🤓 @geteccu @HUnivTO @my_ueg @BiblioCHT #UEGWeek @aegastro
Image from Óscar (@oscarmoralejoMD)
5
17
422
QUALITY OF HUMAN PAPILLOMAVIRUS SCREENING IN WOMEN WITH INFLAMMATORY BOWEL DISEASE (EII-VIP STUDY OF GETECCU) - Happy to collaborate with @yzabanaa @geteccu #ENEIDA @my_ueg #UEGWeek #uegweek2026 #papillomavirus #HPV #screening #ibd @HUnivTO @BiblioCHT
Image from Óscar (@oscarmoralejoMD)
1
7
11
451
EFFICACY AND SAFETY OF SELECTIVE GRANULOCYTE AND MONOCYTE APHERESIS (GMA) WITH ADACOLUMN® IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SPANISH REAL-WORLD CLINICAL PRACTICE: INTERIM ANALYSIS (6-MONTH FOLLOW-UP) OF THE GRACE STUDY @abanades_maria @HUnivTO @my_ueg #adacolumn
Image from Óscar (@oscarmoralejoMD)
2
4
91
Load more